Research
Hormonal
Resmetirom (Rezdiffra), a thyroid hormone receptor-beta (THR-β) agonist, is the first FDA-approved pharmacotherapy for non-cirrhotic MASH in adults with moderate to advanced liver fibrosis (F2-F3), demonstrating significant resolution of MASH and improvement in liver fibrosis compared to placebo.
If you have non-cirrhotic MASH with moderate to advanced fibrosis, ask your doctor about Resmetirom (Rezdiffra). It is the first FDA-approved drug for this condition, taken orally alongside diet and exercise, and has been shown to significantly improve liver health compared to placebo.
StrongSupportsHIGH confidence
Namely, in March 2024, a thyroid hormone receptors β (THR-β) agonist, resmetirom (Rezdiffra™), became the first drug approved by the Food and Drug Administration (FDA) in the United States for the treatment of non-cirrhotic MASH in adults with moderate to progressed liver fibrosis in combination with diet and exercise [20].
Why this rating
Based on Phase 3 MAESTRO-NASH RCT results leading to FDA accelerated approval.
Source
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar et al. · Current Issues in Molecular Biology · 2024
narrative_reviewCited 13×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →